Cargando…
Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
As multidrug-resistant bacteria represent a concerning burden, experts insist on the need for a dramatic rethinking on antibiotic use and development in order to avoid a post-antibiotic era. New and rapidly developable strategies for antimicrobial substances, in particular substances highly potent a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880691/ https://www.ncbi.nlm.nih.gov/pubmed/35215272 http://dx.doi.org/10.3390/ph15020159 |
_version_ | 1784659279848931328 |
---|---|
author | Umstätter, Florian Werner, Julia Zerlin, Leah Mühlberg, Eric Kleist, Christian Klika, Karel D. Hertlein, Tobias Beijer, Barbro Domhan, Cornelius Zimmermann, Stefan Ohlsen, Knut Haberkorn, Uwe Mier, Walter Uhl, Philipp |
author_facet | Umstätter, Florian Werner, Julia Zerlin, Leah Mühlberg, Eric Kleist, Christian Klika, Karel D. Hertlein, Tobias Beijer, Barbro Domhan, Cornelius Zimmermann, Stefan Ohlsen, Knut Haberkorn, Uwe Mier, Walter Uhl, Philipp |
author_sort | Umstätter, Florian |
collection | PubMed |
description | As multidrug-resistant bacteria represent a concerning burden, experts insist on the need for a dramatic rethinking on antibiotic use and development in order to avoid a post-antibiotic era. New and rapidly developable strategies for antimicrobial substances, in particular substances highly potent against multidrug-resistant bacteria, are urgently required. Some of the treatment options currently available for multidrug-resistant bacteria are considerably limited by side effects and unfavorable pharmacokinetics. The glycopeptide vancomycin is considered an antibiotic of last resort. Its use is challenged by bacterial strains exhibiting various types of resistance. Therefore, in this study, highly active polycationic peptide-vancomycin conjugates with varying linker characteristics or the addition of PEG moieties were synthesized to optimize pharmacokinetics while retaining or even increasing antimicrobial activity in comparison to vancomycin. The antimicrobial activity of the novel conjugates was determined by microdilution assays on susceptible and vancomycin-resistant bacterial strains. VAN1 and VAN2, the most promising linker-modified derivatives, were further characterized in vivo with molecular imaging and biodistribution studies in rodents, showing that the linker moiety influences both antimicrobial activity and pharmacokinetics. Encouragingly, VAN2 was able to undercut the resistance breakpoint in microdilution assays on vanB and vanC vancomycin-resistant enterococci. Out of all PEGylated derivatives, VAN:PEG1 and VAN:PEG3 were able to overcome vanC resistance. Biodistribution studies of the novel derivatives revealed significant changes in pharmacokinetics when compared with vancomycin. In conclusion, linker modification of vancomycin-polycationic peptide conjugates represents a promising strategy for the modulation of pharmacokinetic behavior while providing potent antimicrobial activity. |
format | Online Article Text |
id | pubmed-8880691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88806912022-02-26 Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics Umstätter, Florian Werner, Julia Zerlin, Leah Mühlberg, Eric Kleist, Christian Klika, Karel D. Hertlein, Tobias Beijer, Barbro Domhan, Cornelius Zimmermann, Stefan Ohlsen, Knut Haberkorn, Uwe Mier, Walter Uhl, Philipp Pharmaceuticals (Basel) Article As multidrug-resistant bacteria represent a concerning burden, experts insist on the need for a dramatic rethinking on antibiotic use and development in order to avoid a post-antibiotic era. New and rapidly developable strategies for antimicrobial substances, in particular substances highly potent against multidrug-resistant bacteria, are urgently required. Some of the treatment options currently available for multidrug-resistant bacteria are considerably limited by side effects and unfavorable pharmacokinetics. The glycopeptide vancomycin is considered an antibiotic of last resort. Its use is challenged by bacterial strains exhibiting various types of resistance. Therefore, in this study, highly active polycationic peptide-vancomycin conjugates with varying linker characteristics or the addition of PEG moieties were synthesized to optimize pharmacokinetics while retaining or even increasing antimicrobial activity in comparison to vancomycin. The antimicrobial activity of the novel conjugates was determined by microdilution assays on susceptible and vancomycin-resistant bacterial strains. VAN1 and VAN2, the most promising linker-modified derivatives, were further characterized in vivo with molecular imaging and biodistribution studies in rodents, showing that the linker moiety influences both antimicrobial activity and pharmacokinetics. Encouragingly, VAN2 was able to undercut the resistance breakpoint in microdilution assays on vanB and vanC vancomycin-resistant enterococci. Out of all PEGylated derivatives, VAN:PEG1 and VAN:PEG3 were able to overcome vanC resistance. Biodistribution studies of the novel derivatives revealed significant changes in pharmacokinetics when compared with vancomycin. In conclusion, linker modification of vancomycin-polycationic peptide conjugates represents a promising strategy for the modulation of pharmacokinetic behavior while providing potent antimicrobial activity. MDPI 2022-01-28 /pmc/articles/PMC8880691/ /pubmed/35215272 http://dx.doi.org/10.3390/ph15020159 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Umstätter, Florian Werner, Julia Zerlin, Leah Mühlberg, Eric Kleist, Christian Klika, Karel D. Hertlein, Tobias Beijer, Barbro Domhan, Cornelius Zimmermann, Stefan Ohlsen, Knut Haberkorn, Uwe Mier, Walter Uhl, Philipp Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics |
title | Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics |
title_full | Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics |
title_fullStr | Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics |
title_full_unstemmed | Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics |
title_short | Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics |
title_sort | impact of linker modification and pegylation of vancomycin conjugates on structure-activity relationships and pharmacokinetics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880691/ https://www.ncbi.nlm.nih.gov/pubmed/35215272 http://dx.doi.org/10.3390/ph15020159 |
work_keys_str_mv | AT umstatterflorian impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT wernerjulia impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT zerlinleah impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT muhlbergeric impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT kleistchristian impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT klikakareld impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT hertleintobias impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT beijerbarbro impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT domhancornelius impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT zimmermannstefan impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT ohlsenknut impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT haberkornuwe impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT mierwalter impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics AT uhlphilipp impactoflinkermodificationandpegylationofvancomycinconjugatesonstructureactivityrelationshipsandpharmacokinetics |